Endometrial cancer is a common, usually curable malignancy whose treatment frequently involves low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy.
These treatments involve substantial resource commitments and this is increasingly important.
This paper presents a cost minimization analysis of HDR versus LDR brachytherapy in the treatment of endometrial cancer.
The perspective of the analysis is that of the payor, in this case the Ministry of Health.
One course of LDR treatment is compared to two courses of HDR treatment.
The two alternatives are considered to be comparable with respect to local control, survival, and toxicities.
Labor, overhead, and capital costs are accounted for and carefully measured.
A 5% inflation rate is used where applicable.
A univariate sensitivity analysis is performed.
The HDR regime is 22% less expensive compared to the LDR regime.
This is $991.66 per patient or, based on the current workload of this department (30 patients per year) over the useful lifetime of the after loader, $297,498 over 10 years in 1997 dollars.
HDR brachytherapy minimizes costs in the treatment of endometrial cancer relative to I, DR brachytherapy.
These results may be used by other centers to make rational decisions regarding brachytherapy equipment replacement or acquisition.
Mots-clés Pascal : Tumeur maligne, Endomètre, Homme, Curiethérapie, Traitement, Coût, Economie santé, Dose faible, Dose forte, Etude comparative, Appareil génital femelle pathologie, Utérus pathologie, Traitement instrumental
Mots-clés Pascal anglais : Malignant tumor, Endometrium, Human, Curietherapy, Treatment, Costs, Health economy, Low dose, High dose, Comparative study, Female genital diseases, Uterine diseases, Instrumentation therapy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0481111
Code Inist : 002B26L. Création : 19/02/1999.